Five weeks post-MI, both sh-control CDC- and sh-SDF1 CDC-treated hearts exhibited smaller scar mass and increased viable myocardium compared to untreated infarcted controls (Fig 8–C). Here, CXCL12 is linked to myocardial infarction.